Outcomes-based contracts and other value-based arrangements (“VBAs”) between pharmaceutical manufacturers and health care payers have become a “tool in the payment toolbox” VBAs are being employed by payers in Massachusetts and elsewhere to negotiate payments for highly novel pharmaceuticals such as gene therapies, but payers and manufacturers throughout the country are experimenting with VBAs for chronic disease medications as well.
What are the implications for Massachusetts? NEHI’s October 27th briefing will review the status of VBAs in Massachusetts and elsewhere, and lessons learned that may prove useful when Massachusetts state government resumes deliberation on pharmaceutical pricing and payment, largely suspended since the COVID-19 outbreak.
- Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases
- Eleanor Perfetto, PhD, MS, Interim Chief Executive Officer and Executive Vice President of Strategic Initiatives, National Health Council
- Michael Sherman, M.D., Chief Medical Officer, Harvard Pilgrim Health Care
- Dan Wygal, Executive Director of Contract and Channel Strategy, AstraZeneca